Skip to main content
Top
Published in: Breast Cancer Research 6/2008

Open Access 01-12-2008 | Research article

Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study

Authors: Thomas P Ahern, Timothy L Lash, Henrik T Sørensen, Lars Pedersen

Published in: Breast Cancer Research | Issue 6/2008

Login to get access

Abstract

Introduction

Laboratory and epidemiologic studies have suggested a modifying effect of cardiac glycosides (for example, digoxin and digitoxin) on cancer risk. We explored the association between digoxin treatment and invasive breast cancer incidence among postmenopausal Danish women.

Methods

We used Danish registries to identify 5,565 postmenopausal women diagnosed with incident invasive breast carcinoma between 1 January 1991 and 31 December 2007, and 55,650 matched population controls. Cardiac glycoside prescriptions were ascertained from county prescription registries. All subjects had at least 2 years of recorded prescription drug and medical history data. We estimated the odds ratio associating digoxin use with breast cancer in conditional logistic regression models adjusted for age, county of residence, and use of anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, and hormone replacement therapy. We also explored the impact of confounding by indication and detection bias.

Results

Digoxin was the sole cardiac glycoside prescribed to subjects during the study period. There were 324 breast cancer cases (5.8%) and 2,546 controls (4.6%) with a history of digoxin use at least 1 year before their index date (adjusted odds ratio (OR): 1.30; 95% confidence interval: 1.14 to 1.48). The breast cancer OR increased modestly with increasing duration of digoxin exposure (adjusted OR for 7 to 18 years of digoxin use: 1.39; 95% confidence interval: 1.10 to 1.74). The association was robust to adjustment for age, receipt of hormone replacement therapy, coprescribed drugs, and confounding by indication. A comparison of screening mammography rates between cases and controls showed no evidence of detection bias.

Conclusions

Our results suggest that digoxin treatment increases the risk of invasive breast cancer among postmenopausal women.
Literature
1.
go back to reference Harrison TR, Fauci AS: Harrison's Principles of Internal Medicine. 1998, New York, NY: McGraw-Hill, Health Professions Division, 1264-1295. 14 Harrison TR, Fauci AS: Harrison's Principles of Internal Medicine. 1998, New York, NY: McGraw-Hill, Health Professions Division, 1264-1295. 14
2.
go back to reference Stenkvist B, Bengtsson E, Eriksson O, Holmquist J, Nordin B, Westman-Naeser S: Cardiac glycosides and breast cancer. Lancet. 1979, 1: 563-10.1016/S0140-6736(79)90996-6.CrossRefPubMed Stenkvist B, Bengtsson E, Eriksson O, Holmquist J, Nordin B, Westman-Naeser S: Cardiac glycosides and breast cancer. Lancet. 1979, 1: 563-10.1016/S0140-6736(79)90996-6.CrossRefPubMed
3.
go back to reference Stenkvist B, Pengtsson E, Dahlqvist B, Eriksson O, Jarkrans T, Nordin B: Cardiac glycosides and breast cancer, revisited. N Engl J Med. 1982, 306: 484-PubMed Stenkvist B, Pengtsson E, Dahlqvist B, Eriksson O, Jarkrans T, Nordin B: Cardiac glycosides and breast cancer, revisited. N Engl J Med. 1982, 306: 484-PubMed
4.
go back to reference Stenkvist B: Is digitalis a therapy for breast carcinoma?. Oncol Rep. 1999, 6: 493-496.PubMed Stenkvist B: Is digitalis a therapy for breast carcinoma?. Oncol Rep. 1999, 6: 493-496.PubMed
5.
go back to reference Chen JQ, Contreras RG, Wang R, Fernandez SV, Shoshani L, Russo IH, Cereijido M, Russo J: Sodium/potassium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides: A new paradigm for development of anti- breast cancer drugs?. Breast Cancer Res Treat. 2006, 96: 1-15. 10.1007/s10549-005-9053-3.CrossRefPubMed Chen JQ, Contreras RG, Wang R, Fernandez SV, Shoshani L, Russo IH, Cereijido M, Russo J: Sodium/potassium ATPase (Na+, K+-ATPase) and ouabain/related cardiac glycosides: A new paradigm for development of anti- breast cancer drugs?. Breast Cancer Res Treat. 2006, 96: 1-15. 10.1007/s10549-005-9053-3.CrossRefPubMed
6.
go back to reference Newman RA, Yang P, Pawlus AD, Block KI: Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 2008, 8: 36-49. 10.1124/mi.8.1.8.CrossRefPubMed Newman RA, Yang P, Pawlus AD, Block KI: Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 2008, 8: 36-49. 10.1124/mi.8.1.8.CrossRefPubMed
7.
go back to reference Haux J, Klepp O, Spigset O, Tretli S: Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer. 2001, 1: 11-10.1186/1471-2407-1-11.CrossRefPubMedPubMedCentral Haux J, Klepp O, Spigset O, Tretli S: Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer. 2001, 1: 11-10.1186/1471-2407-1-11.CrossRefPubMedPubMedCentral
8.
9.
go back to reference Sorensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA: Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008, 336: 813-816. 10.1136/bmj.39507.551644.BE.CrossRefPubMedPubMedCentral Sorensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA: Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008, 336: 813-816. 10.1136/bmj.39507.551644.BE.CrossRefPubMedPubMedCentral
10.
go back to reference Sorensen HT, Skriver MV, Friis S, McLaughlin JK, Blot WJ, Baron JA: Use of antibiotics and risk of breast cancer: a population-based case-control study. Br J Cancer. 2005, 92: 594-596.PubMed Sorensen HT, Skriver MV, Friis S, McLaughlin JK, Blot WJ, Baron JA: Use of antibiotics and risk of breast cancer: a population-based case-control study. Br J Cancer. 2005, 92: 594-596.PubMed
11.
go back to reference Frank L: Epidemiology. When an entire country is a cohort. Science. 2000, 287: 2398-2399. 10.1126/science.287.5462.2398.CrossRefPubMed Frank L: Epidemiology. When an entire country is a cohort. Science. 2000, 287: 2398-2399. 10.1126/science.287.5462.2398.CrossRefPubMed
12.
go back to reference Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT: Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol. 2003, 98: 1305-1308.PubMed Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT: Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol. 2003, 98: 1305-1308.PubMed
13.
go back to reference Lash TL, Pedersen L, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Hamilton-Dutoit S, Garne JP, Ewertz M, Sørensen HT: Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer. 2008, 99: 616-621. 10.1038/sj.bjc.6604533.CrossRefPubMedPubMedCentral Lash TL, Pedersen L, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Hamilton-Dutoit S, Garne JP, Ewertz M, Sørensen HT: Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer. 2008, 99: 616-621. 10.1038/sj.bjc.6604533.CrossRefPubMedPubMedCentral
15.
go back to reference Schulman S, Lindmarker P: Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med. 2000, 342: 1953-1958. 10.1056/NEJM200006293422604.CrossRefPubMed Schulman S, Lindmarker P: Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med. 2000, 342: 1953-1958. 10.1056/NEJM200006293422604.CrossRefPubMed
16.
go back to reference McGettigan P, Han P, Jones L, Whitaker D, Henry D: Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol. 2008, 65: 927-934. 10.1111/j.1365-2125.2008.03121.x.CrossRefPubMedPubMedCentral McGettigan P, Han P, Jones L, Whitaker D, Henry D: Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol. 2008, 65: 927-934. 10.1111/j.1365-2125.2008.03121.x.CrossRefPubMedPubMedCentral
17.
go back to reference Moysich KB, Beehler GP, Zirpoli G, Choi JY, Baker JA: Use of common medications and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008, 17: 1564-1595. 10.1158/1055-9965.EPI-07-2828.CrossRefPubMed Moysich KB, Beehler GP, Zirpoli G, Choi JY, Baker JA: Use of common medications and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008, 17: 1564-1595. 10.1158/1055-9965.EPI-07-2828.CrossRefPubMed
18.
go back to reference Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI: Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004, 291: 2433-2440. 10.1001/jama.291.20.2433.CrossRefPubMed Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI: Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004, 291: 2433-2440. 10.1001/jama.291.20.2433.CrossRefPubMed
19.
go back to reference Cuzick J: Hormone replacement therapy and the risk of breast cancer. Eur J Cancer. 2008, 44: 2344-2349. 10.1016/j.ejca.2008.07.041.CrossRefPubMed Cuzick J: Hormone replacement therapy and the risk of breast cancer. Eur J Cancer. 2008, 44: 2344-2349. 10.1016/j.ejca.2008.07.041.CrossRefPubMed
20.
go back to reference Rothman KJ, Greenland S, Lash TL: Case-control studies. Modern Epidemiology. 2008, Philadelphia, PA: Lippincott Williams & Wilkins, 111-125. 3 Rothman KJ, Greenland S, Lash TL: Case-control studies. Modern Epidemiology. 2008, Philadelphia, PA: Lippincott Williams & Wilkins, 111-125. 3
21.
go back to reference Stenkvist B, Bengtsson E, Eklund G, Eriksson O, Holmquist J, Nordin B, Westman-Naeser S: Evidence of a modifying influence of heart glucosides on the development of breast cancer. Anal Quant Cytol. 1980, 2: 49-54.PubMed Stenkvist B, Bengtsson E, Eklund G, Eriksson O, Holmquist J, Nordin B, Westman-Naeser S: Evidence of a modifying influence of heart glucosides on the development of breast cancer. Anal Quant Cytol. 1980, 2: 49-54.PubMed
22.
go back to reference Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A: Risk factors for male breast cancer – a case-control study from Scandinavia. Acta Oncol. 2001, 40: 467-471. 10.1080/028418601750288181.CrossRefPubMed Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A: Risk factors for male breast cancer – a case-control study from Scandinavia. Acta Oncol. 2001, 40: 467-471. 10.1080/028418601750288181.CrossRefPubMed
23.
go back to reference Cove DH, Barker GA: Digoxin and hormone receptors. Lancet. 1979, 2: 204-10.1016/S0140-6736(79)91475-2.CrossRefPubMed Cove DH, Barker GA: Digoxin and hormone receptors. Lancet. 1979, 2: 204-10.1016/S0140-6736(79)91475-2.CrossRefPubMed
24.
go back to reference Freyberger A, Schmuck G: Screening for estrogenicity and anti-estrogenicity: a critical evaluation of an MVLN cell-based transactivation assay. Toxicol Lett. 2005, 155: 1-13. 10.1016/j.toxlet.2004.06.014.CrossRefPubMed Freyberger A, Schmuck G: Screening for estrogenicity and anti-estrogenicity: a critical evaluation of an MVLN cell-based transactivation assay. Toxicol Lett. 2005, 155: 1-13. 10.1016/j.toxlet.2004.06.014.CrossRefPubMed
25.
26.
go back to reference Nesher M, Shpolansky U, Rosen H, Lichtstein D: The digitalis-like steroid hormones: new mechanisms of action and biological significance. Life Sci. 2007, 80: 2093-2107. 10.1016/j.lfs.2007.03.013.CrossRefPubMed Nesher M, Shpolansky U, Rosen H, Lichtstein D: The digitalis-like steroid hormones: new mechanisms of action and biological significance. Life Sci. 2007, 80: 2093-2107. 10.1016/j.lfs.2007.03.013.CrossRefPubMed
27.
go back to reference Rifka SM, Pita JC, Loriaux DL: Mechanism of interaction of digitalis with estradiol binding sites in rat uteri. Endocrinology. 1976, 99: 1091-1096.CrossRefPubMed Rifka SM, Pita JC, Loriaux DL: Mechanism of interaction of digitalis with estradiol binding sites in rat uteri. Endocrinology. 1976, 99: 1091-1096.CrossRefPubMed
28.
go back to reference Rothman KJ, Greenland S, Lash TL: Validity in epidemiologic studies. Modern Epidemiology. 2008, Philadelphia: Lippincott Williams & Wilkins, 134-137. 3 Rothman KJ, Greenland S, Lash TL: Validity in epidemiologic studies. Modern Epidemiology. 2008, Philadelphia: Lippincott Williams & Wilkins, 134-137. 3
29.
go back to reference Russo J, Moral R, Balogh GA, Mailo D, Russo IH: The protective role of pregnancy in breast cancer. Breast Cancer Res. 2005, 7: 131-142. 10.1186/bcr1029.CrossRefPubMedPubMedCentral Russo J, Moral R, Balogh GA, Mailo D, Russo IH: The protective role of pregnancy in breast cancer. Breast Cancer Res. 2005, 7: 131-142. 10.1186/bcr1029.CrossRefPubMedPubMedCentral
30.
go back to reference Hjartaker A, Langseth H, Weiderpass E: Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol. 2008, 630: 72-93.CrossRefPubMed Hjartaker A, Langseth H, Weiderpass E: Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol. 2008, 630: 72-93.CrossRefPubMed
31.
go back to reference Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA: Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am. 2008, 37: 663-684. 10.1016/j.ecl.2008.06.004.CrossRefPubMed Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA: Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am. 2008, 37: 663-684. 10.1016/j.ecl.2008.06.004.CrossRefPubMed
Metadata
Title
Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study
Authors
Thomas P Ahern
Timothy L Lash
Henrik T Sørensen
Lars Pedersen
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2205

Other articles of this Issue 6/2008

Breast Cancer Research 6/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine